Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial-Reference-Cited by-同舟云学术

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

Published:2011-01-15 Issue:2 Volume:126 Page:463-470
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Bernsdorf Mogens,Ingvar Christian,Jörgensen Leif,Tuxen Malgorzata K.,Jakobsen Erik H.,Saetersdal Anna,Kimper-Karl Marie Louise,Kroman Niels,Balslev Eva,Ejlertsen Bent

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-011-1352-2.pdf

Reference28 articles.

1. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A et al (2008) Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 26:778–785

2. Kaufmann M, von MG, Bear HD, Buzdar A, McGale P, Bonnefoi H et al (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927–1934

3. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194

4. Mieog JS, van der Hage JA, van d V (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev CD005002

5. Dieras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L et al (2004) Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22:4958–4965

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR mutations and abnormal trafficking in cancers;Molecular Biology Reports;2024-08-21

2. Exploring the Potential of Nanomolecular Therapeutic Therapy Options, and Novel Biomarkers in Triple-negative Breast Cancer Treatment;Current Cancer Therapy Reviews;2024-06-11

3. Constructing a novel prognostic model for triple-negative breast cancer based on genes associated with vasculogenic mimicry;Aging;2024-05-08

4. Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer;Frontiers in Oncology;2024-04-18

5. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway;Cell Death & Disease;2024-04-12